Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...
Hyperfine Sees Q3 Sales $3.400M vs $3.507M Est Becton Dickinson Narrows FY2025 Sales Guidance from $21.800B-$21.900B to $21.800B vs $21.863B Est Orchid Island Capital Announces Estimated Q3 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback